1	JAK signaling was involved in the pathogenesis of Polymyalgia Rheumatica							
2	Fan Yang ^{1,*} , Xinlei Ma ^{2,*} , Bei Xu ^{2,*} , Yiduo Sun ² , Mengdi Jiang ² , Chunyun Ren ² ,							
3	Chuanying Sun ² , Junyu Liang ² , Heng Cao ² , Danyi Xu ² ,Lihuan Yue ² , Liqin Xu ² , Jin Lin ² ,							
4	Weiqian Chen ²							
5								
6	¹ State Key Laboratory of Infectious Diseases Diagnosis and Treatment, the First							
7	Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,310003							
8	Zhejiang, China							
9	² Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of							
10	Medicine, Hangzhou, 310003 Zhejiang, China							
11								
12	Running title: JAK signaling was highly activated in patients with PMR							
13								
14	* Fan Yang, Xinlei Ma, and Bei Xu equally contributed to this manuscript.							
15								
16	Correspondence to: Weiqian Chen, Email: cwq678@zju.edu.cn , Address: #79, Qing							
17	Chun Road, Hangzhou, 310003, Zhejiang, China							
18								
19								
20								
21								
~ 1								
22								
23								
24								
25								
23								
26								

27 Abstract

Objectives. Polymyalgia Rheumatica (PMR) is a common inflammatory disease in
elderly persons whose pathogenesis is unclear. We aimed to explore the
pathogenetic features of PMR and find a new therapeutic strategy.

Methods. We included 11 patients with PMR and 20 age-matched and sex-matched healthy controls (HC) in this study. The disease features were described. The gene expression profiles were analyzed in peripheral blood mononuclear cells (PBMCs) by RNA sequencing and were confirmed by RT-PCR. We also tested gene expression profiles in five patients with PMR after tofacitinib therapy.

36 **Results.** Patients with PMR experienced pain with high disease activity scores. The 37 gene expression of PBMCs in patients with PMR differed from that in HC by RNA 38 sequencing. GO and KEGG analysis demonstrated that inflammatory response and 39 cytokine-cytokine receptor interaction were the most remarkable pathways. There 40 were markedly expanded IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1, 41 S100A8, S100A12, and IL17RA expressions. Those genes may trigger the JAK signaling. 42 Furthermore, tofacitinib, a pan JAK inhibitor, effectively treated five patients with 43 PMR, leading to clinical remission and a significant decrease in inflammatory genes.

44 Conclusions. Many inflammatory genes associated with JAK signaling were increased
45 in patients with PMR, suggesting an important role of JAK signaling in PMR disease
46 development. JAK inhibitors may effectively treat PMR.

47

48 **Keywords:** Polymyalgia Rheumatica, Inflammatory pathway, JAK signaling

49

50 Key messages

- Patients with PMR had significant inflammatory genes expression. JAK signaling
 may be highly activated.
- 53 2. Tofacitinib may treat PMR with clinical remission and a significant decrease in54 inflammatory genes.
- 55
- 56

57 Introduction

58 Polymyalgia Rheumatica (PMR) is an inflammatory disease in elderly patients (>50 59 years old) characterized by pain and early morning stiffness in the shoulder, neck, and 60 pelvic girdle[1, 2]. Blood tests show higher serum levels of inflammatory markers such 61 as c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in these 62 patients; however, negative results of rheumatoid factor (RF), and anti-citrullinated 63 protein/peptide antibody (ACPA), anti-nuclear antibodies (ANA), and human 64 leukocyte antigen B27 (HLA-B27). Sometimes, it is difficult to distinguish patients 65 with PMR from those with Rheumatoid arthritis (RA) who are negative for RF or 66 ACPA. However, patients with PMR usually have hallmark features with a dramatic 67 response to glucocorticoids.

PMR is a multi-gene susceptibility disease, and many alleles may be involved in the pathogenesis of this disease[3]. Interleukin 6 (IL6) polymorphisms are associated with PMR risk or severity[4]. Aging is a crucial element as PMR occurs in elderly patients. Aging may increase the susceptibility to infectious agents, immune responses, or the release of cytokines[5]. However, its pathogenesis has not been fully elucidated. Further pathogenetic research and the discovery of new targets can provide more ideas for the treatment of PMR.

75

76 Methods

77 Subjects

78 This cohort study included PMR patients who fulfilled the 1982 Chuang criteria[6] 79 between September 2020 and September 2021. They did not receive any 80 glucocorticoids or biological agents during the three-month period that preceded 81 their inclusion in the study. There were twenty age-matched and sex-matched 82 healthy controls (HC) without connective tissue disorders, neoplasms, or current 83 infections. All patients gave their written informed consent. The study was 84 performed according to the recommendations of the Declaration of Helsinki and was 85 approved by the Medical Ethical Committee of the First Affiliated Hospital, Zhejiang 86 University (IIT20200070C-R1).

87

88 Clinical features

- 89 Patient information on demographic data, clinical features, serological profiles, and
- 90 medications was obtained from medical records. Current PMR disease activity was
- 91 measured using the previous score sheet[7].
- 92

93 RNA sequence analysis and Semiquantitative Real-Time PCR

- 94 Peripheral blood mononuclear cells (PBMCs) were isolated from patients with PMR
- 95 and HC. Total RNA and RNA-seq libraries were prepared. Sequencing was performed
- 96 on an Illumina HiSeq1500. Some genes were tested by semiquantitative Real-Time
- 97 PCR. The primers for the target gene were described as below.
- 98 IL6R Forward: 5'-CCCCTCAGCAATGTTGTTGT-3'
- 99 Reverse: 5'-CTCCGGGACTGCTAACTGG-3'
- 100 IL1B Forward: 5'-ATGATGGCTTATTACAGTGGCAA-3'
- 101 Reverse: 5'-GTCGGAGATTCGTAGCTGGA-3'
- 102 Interleukin 1 receptor type 1 (IL1R1)
- 103 Forward: 5'-ATGAAATTGATGTTCGTCCCTGT-3'
- 104 Reverse: 5'-ACCACGCAATAGTAATGTCCTG-3'
- 105 Janus kinase (JAK) 2
- 106 Forward: 5'-TCTGGGGAGTATGTTGCAGAA-3'
- 107 Reverse: 5'-AGACATGGTTGGGTGGATACC-3'
- 108 Toll Like Receptor 2 (TLR2)
- **109** Forward: 5'-ATCCTCCAATCAGGCTTCTCT-3'
- 110 Reverse: 5'-GGACAGGTCAAGGCTTTTTACA-3'
- 111 TLR4 Forward: 5'-AGACCTGTCCCTGAACCCTAT-3'
- 112 Reverse: 5'-CGATGGACTTCTAAACCAGCCA-3'
- 113 TLR8 Forward: 5'-ATGTTCCTTCAGTCGTCAATGC-3'
- 114 Reverse: 5'-TTGCTGCACTCTGCAATAACT-3'
- 115 Interleukin 17 Receptor A (IL17RA)
- 116 Forward: 5'-GCTTCACCCTGTGGAACGAAT-3'
- 117 Reverse: 5'-TATGTGGTGCATGTGCTCAAA-3'
- 118 Complement receptor 1 (CR1)
- **119** Forward: 5'-AGAGGGACGAGCTTCGACC-3'

120 Reverse: 5'-TCAGGACGGCATTCGTACTTT-3'

- 121 C-C motif chemokine receptor 1 (CCR1)
- 122 Forward: 5'-GACTATGACACGACCACAGAGT-3'
- 123 Reverse: 5'-CCAACCAGGCCAATGACAAATA-3'
- 124 S100 calcium-binding protein A8 (S100A8)
- 125 Forward: 5'-ATGCCGTCTACAGGGATGAC-3'
- 126 Reverse: 5'-ACTGAGGACACTCGGTCTCTA-3'
- 127 S100A12 Forward: 5'-AGCATCTGGAGGGAATTGTCA-3'
- 128 Reverse: 5'-GCAATGGCTACCAGGGATATGAA-3'
- 129 GAPDH Forward: 5'-GGAGCGAGATCCCTCCAAAAT-3'

130 Reverse: 5'-GGCTGTTGTCATACTTCTCATGG-3',

131 GAPDH was considered as a normalization control. The data were

132 examined using the $2^{\Delta^{CT}}$ method and results were expressed as a fold increase.

133 Each sample was tested in triplicate, and tests were repeated three times.

134

135 Statistical analysis

Results are expressed as median and standard deviation (SD). Comparisons between
two groups were performed using the nonparametric Mann-Whitney test. *P*-values
< 0.05 were considered statistically significant. All statistical analyses were
performed using SPSS software, version 18.0.

140

141 Results

142 The patients with PMR were in a state of high inflammation

The baseline characteristics of the 11 PMR patients and 20 healthy controls are presented in the supplementary material. There were no significant differences in age and sex between the PMR group and HC. In the PMR group, patients who experienced pain in the shoulder, neck, and pelvic girdle had a mean VS score of 4.9 \pm 2.2. They had higher serum levels of CRP (3.9 \pm 3.1 mg/dl, normal range 0–0.08) and ESR (67.1 \pm 24.9 mm/L, normal range 0–20). Disease activity scores[7] ranged from 9.33 to 27.15 with a mean value of 16.3 \pm 7.3 (Table 1), which suggests medium

150 or high disease activity in these patients who were categorized as active PMR (PMR-

A). They were all negative for RF, ACPA, ANA, and HLA-B27. They represented no
remarkable wrist, metacarpophalangeal, proximal interphalangeal, knee, and digital
joint swelling.

154

155 Patients with PMR had significant inflammatory gene expression profiles

156 The principal component analysis (PCA) and heatmap showed that gene expressions 157 of PBMCs in patients with PMR-A differed from those of HC (Fig. 1A, B). GO analysis demonstrated that the inflammatory response (FDR 6.74 \times 10⁻¹⁵, included 58 158 significantly altered genes), plasma membrane (7.30×10^{-12}) , included 254 159 160 significantly altered genes), integral component of the plasma membrane (5.23 \times 10^{-11} , included 115 significantly altered genes), extracellular space (2.76 × 10^{-8} , 161 included 103 significantly altered genes), extracellular region (4.36 \times 10⁻⁸, included 162 116 significantly altered genes), response to lipopolysaccharide (2.42×10^{-6} , included 163 27 significantly altered genes), integral component of membrane (1.36 \times 10⁻⁵. 164 included 270 significantly altered genes), immune response $(1.21 \times 10^{-4}, \text{ included } 42)$ 165 significantly altered genes), cell surface (2.04×10^{-4}) , innate immune response (4.29)166 $\times 10^{-4}$), response to glucocorticoid (7.43 $\times 10^{-4}$), IL-1 β secretion (1.67 $\times 10^{-3}$) were 12 167 168 significant predominant pathways in PMR (Fig. 1C). The cytokine-mediated signaling 169 pathway, the positive regulation of IL-6 production, and the MyD88-dependent toll-170 like receptor (TLR) signaling pathway were also significantly altered. KEGG analysis 171 revealed that the cytokine-cytokine receptor interaction was the most remarkable 172 pathway (FDR 2.85 \times 10⁻⁵) (Fig. 1D). GO and KEGG results demonstrated patients 173 with PMR had significant inflammatory gene expression profiles.

174

Abundant inflammatory genes that may activate Janus tyrosine kinase (JAK)signaling

177Volcano results demonstrated that many genes expression were significantly178increased; for example, TLR8 ($p = 1.95 \times 10^{-20}$), IL17RA ($p = 3.27 \times 10^{-17}$), IL6R (p =179 6.71×10^{-16}), CR1 ($p = 1.14 \times 10^{-14}$), TLR2 ($p = 2.99 \times 10^{-14}$), TLR4 ($p = 8.48 \times 10^{-14}$),180CCR1 ($p = 7.75 \times 10^{-13}$), JAK2 ($p = 6.57 \times 10^{-6}$), IL1R1 ($p = 1.72 \times 10^{-5}$), IL1B ($p = 2.87 \times 10^{-5}$), S100A8 ($p = 2.14 \times 10^{-3}$), and S100A12 ($p = 2.76 \times 10^{-3}$) (Fig. 2A).

We also confirmed that the above genes were all increased via Real-Time PCR (Fig. 2B). They can activate the JAK-signal transducer and activator of transcription (STAT) pathway[8-18]. They were also related to the function of monocytes, T cells, and neutrophils. The JAK-STAT pathway may be crucial in the pathogenesis of PMR.

186 Tofacitinib therapy for patients with PMR

187 As we know, glucocorticoids are the first-line drugs in the treatment of PMR. 188 However, they come with lots of side effects. Zhang et al. demonstrated that JAK1 189 and JAK3 were involved in chronic inflammation of media and large arteries in an 190 animal model of giant cell arteritis (GCA), JAK inhibitor (JAKi) tofacitinib effectively 191 suppressed innate and adaptive immunity in the vessel wall by reducing the 192 proliferation rates of lesional T cells and their interferon-y, IL-17, and IL-21 193 expressions[19]. We demonstrated that the expression of JAK2 was increased in 194 PBMCs from patients with PMR (Figure 1B, C). Interestingly, Tofacitinib was tried in 3 195 patients with PMR as a steroid-sparing agent (https://isr.ie/abstracts/a-review-of-196 patients-started-on-janus-kinase-inhibitor-jaki-in-university-hospital-waterford/).

197 Another JAKi Baricitinib lowered rapidly disease activity and exerted a significant 198 steroid-sparing effect in 6 cases with refractory PMR and/or GCA [20]. JAKi appears 199 as an appealing option for treating patients with PMR if they have refractory disease 200 course or other diseases such as diabetes mellitus or osteoporosis which is relatively 201 contraindicated for use of glucocorticoids. To some extent, RA and PMR are two 202 inflammatory diseases with similar manifestations. JAKi was used for the treatment 203 of RA. JAKi may be one choice for PMR. In our study, five patients with PMR refused 204 to take steroids for fear of their side effects, because four patients have osteoporosis. 205 They hopefully have a quick remission but no steroid or no injection such as 206 tocilizumab. They agree with oral Tofacitinib therapy. Dramatically, their pain 207 disappeared and many genes were decreased after tofacitinib therapy. One representative case is shown in Fig. 2C, D. There were no adverse events such as 208 209 upper respiratory infection or herpes zoster during the 3-6-month period of 210 treatment with tofacitinib.

Furthermore, the gene expression profiles of patients with PMR that were in remission after tofacitinib therapy (the PMR-C group) differed from those of patients in the PMR-A group and were similar to those of HC group (Fig. 1B). These results

suggested that patients with PMR-C had attained complete serological remissionafter tofacitinib therapy.

216 Discussion

217 PMR is a classic inflammatory disease with an acute onset but an unknown cause. IL-218 6 is one of the key pro-inflammatory cytokines involved in the pathogenesis of PMR. 219 IL-6 and IL-1 β were increased in the inflamed trapezius and lateral femoral muscles 220 of PMR patients[8]. IL-6 can activate the JAK-STAT signaling via IL6R. Meanwhile, IL-221 1β binding to IL1R1 can form the high-affinity IL-1R complex, which mediates the 222 Nuclear factor kappa B (NF- κ B), Mitogen-activated protein kinase (MAPK), and JAK-223 STAT activation and promotes the inflammatory response[9]. TLR2, TLR4, and TLR8 224 were highly expressed in peripheral blood leukocytes, particularly in monocytes and 225 macrophages. TLRs can lead to NF-κB activation, cytokine secretion, and the 226 inflammatory response. TLR2/TLR4 in collaboration with the JAK-STAT signaling 227 regulates endotoxemia and inflammation[10, 11]. STAT-1 was required for TLR8 228 transcriptional activity[12]. Furthermore, TLR4 was associated with increased 229 susceptibility to PMR[21].

230 S100A8 and S100A12 are calcium-binding, zinc-binding proteins, and inflammatory 231 mediators. S100A8 can induce the JAK1/2-dependent signaling[13]. S100A12 was 232 induced by IL-6 via JAK signaling[14]. CCR1 and CR1 play critical roles in the process 233 of inflammation. CCR1 was involved in the regulation of smoke-induced 234 inflammation via JAK/STAT3 signaling[15]. CCR1 may also play a role in macrophage 235 and endothelial cell infiltration in experimental arthritis models partly through 236 activating JAK signaling[16]. Complement activation can be induced during 237 inflammation, which is further normalized by a JAK1/2 inhibitor[17]. The number of 238 Th17 cells was increased in the blood of PMR patients. CD161⁺CD4⁺T cells, which are precursors of Th17 cells, differentiated into Th17 cells through STAT-1/STAT-3 239 240 phosphorylation[18]. We found that IL6R, IL1B, IL1R1, TLR2, TLR4, TLR8, S100A8, 241 S100A12, CCR1, CR1, and IL17RA expression was increased in PBMCs from patients 242 with PMR. These genes may be partly involved in the pathogenesis of PMR via JAK-243 STAT signaling.

JAK1 and JAK3 were involved in chronic inflammation of media and large arteries in an animal model of GCA, tofacitinib effectively suppressed innate and adaptive immunity in the vessel wall [19]. Furthermore, five patients with PMR had a good response to tofacitinib therapy in our study. We have registered a clinical trial titled "a prospective study on the efficacy and safety of tofacitinib in the treatment of PMR" (ChiCTR2000038253) on the website (http://www.chictr.org.cn/). More data will be published in the future.

Our study has some limitations. The number of patients was small. We do not finish the functional experiment of candidate genes involved in the pathogenesis of PMR. PMR is closely associated with GCA. The patients with PMR in this study did not simultaneously have a GCA. Further studies are needed to investigate the clinical role and mechanism of action of candidate genes in PMR.

256

257 Conclusion

258 Many inflammatory genes associated with JAK signaling are highly enriched in 259 PBMCs from patients with PMR. Tofacitinib, a pan JAK inhibitor effectively treated 260 the PMR patients with clinical remission and sharply decreased in CRP and ESR in this 261 pre-clinical trial study. Tofacitinib may effectively treat PMR patients.

262

263 Disclosure statement: The authors have declared no conflicts of interest.

264

265 Funding: This work was supported in part by grants from Natural Science Foundation

266 of China (82171768).

267

268 Data availability statement: All the data can be available upon reasonable request.

269

270 References

271 1 Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term
 272 management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol
 2020;16(9):481-95.

274 2 Buttgereit F, Matteson EL, Dejaco C. Polymyalgia Rheumatica and Giant Cell 275 Arteritis. Jama 2020;324(10):993-4.

276 Prieto-Peña D, Castañeda S, Atienza-Mateo B, Blanco R, González-Gay MA. 3 277 Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Expert Rev 278 Clin Immunol 2021;17(3):225-32. 279 4 Guggino G, Ferrante A, Macaluso F, Triolo G, Ciccia F. Pathogenesis of polymyalgia 280 rheumatica. Reumatismo 2018;70(1):10-7. 281 Carvajal Alegria G, Boukhlal S, Cornec D, Devauchelle-Pensec V. The 5 282 pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun 283 Rev 2020;19(11):102670. 284 6 Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-285 year epidemiologic and clinical study. Ann Intern Med 1982;97(5):672-80. 286 7 Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum 287 Dis 2004;63(10):1279-83. 288 Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of 8 289 inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum 290 2010;62(12):3768-75. 291 9 Biffi G, Oni TE, Spielman B, et al. IL1-Induced JAK/STAT Signaling Is Antagonized 292 by TGF β to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer 293 Discov 2019;9(2):282-301. 294 10 Paracha RZ, Ahmad J, Ali A, et al. Formal modelling of toll like receptor 4 and 295 JAK/STAT signalling pathways: insight into the roles of SOCS-1, interferon- β and 296 proinflammatory cytokines in sepsis. PLoS One 2014;9(9):e108466. 297 11 Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor, 298 and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 299 2007;82(2):237-43. 300 12 Zannetti C, Bonnay F, Takeshita F, et al. C/EBP{delta} and STAT-1 are required 301 for TLR8 transcriptional activity. J Biol Chem 2010;285(45):34773-80. 302 Diklić M, Mitrović-Ajtić O, Subotički T, et al. IL6 inhibition of inflammatory 13 303 S100A8/9 proteins is NF-κB mediated in essential thrombocythemia. Cell Biochem 304 Funct 2020;38(4):362-72. 305 14 Hasegawa T, Kosaki A, Kimura T, et al. The regulation of EN-RAGE (S100A12) 306 gene expression in human THP-1 macrophages. Atherosclerosis 2003;171(2):211-8. 307 15 Zhao K, Dong R, Yu Y, et al. Cigarette smoke-induced lung inflammation in COPD 308 /NF-κB mediated CCR1/JAK/STAT via pathway. Aging (Albany NY) 309 2020;12(10):9125-38. Shahrara S, Amin MA, Woods JM, Haines GK, Koch AE. Chemokine receptor 310 16 311 expression and in vivo signaling pathways in the joints of rats with adjuvant-induced 312 arthritis. Arthritis Rheum 2003;48(12):3568-83. 313 17 Yan B, Freiwald T, Chauss D, et al. SARS-CoV-2 drives JAK1/2-dependent local 314 complement hyperactivation. Sci Immunol 2021;6(58). 315 18 Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing 316 CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. 317 Arthritis Rheum 2012;64(11):3788-98. 318 19 Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of 319 JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large 320 Vessel Vasculitis. Circulation 2018;137(18):1934-48. 321 20 Camellino D, Dejaco C, Giusti A, et al. AB0379 Baricitinib in polymyalgia 322 rheumatica and giant cell arteritis: report of six cases. Annals of the Rheumatic 323 Diseases 2021;80(Suppl 1):1216-7. 324 21 Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of 325 giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.

326 Rheumatology (Oxford) 2017;56(4):506-15.

- 327
- 328
- 329
- 330
- 331
- 332

Table 1 Demographic and clinical parameters of PMR and healthy controls on study

334 entry

	PMR-A (<i>n</i> = 11)	Healthy controls (n =20)	P value
Age, mean ± SD years	68.0±8.3	63.7±9.8	0.142
Female/male	10/1	17/3	0.67
Disease duration, mean ± SD months	10.4±14.8	NA	
Pain, VS score 0-10, mean ± SD	4.9±2.2	NA	
Physician global assessment, VS score 0-10, mean ± SD	4.7±2.9	NA	
Morning stiffness, min, mean ± SD	17.3±21.8	NA	
EUL, mean ± SD	1.0±0.8	0	
CRP, mean±SD mg/dl	3.9±3.1	0.2±0.2	<0.0001
ESR, mean±SD mm/h	67.1 ±24.9	10.5±5.2	<0.0001
Disease activity scores, mean±SD	16.3±7.3	NA	

335

these PMR patients with high disease activity: PMR-A, NA: not applicable, VS: visual analogue scale,

336 EUL: ability to elevate the upper limbs; C-reactive protein (CRP), normal range 0–0.08 mg/dl;

337 Erythrocyte sedimentation rate (ESR), normal range 0–20mm/h.

338

339

340

341

- 342
- 343
- 344
- 345
- 346
- 347
- 348 Figure legends

349	FIG. 1 The	patients	with	PMR	had	а	significant	inflammatory	gene	expression
350	profile.									

(A and B) Principal component analysis (PCA) and heatmap showed that gene
expression of PBMCs was different among patients with active PMR (PMR-A, n=11),
with PMR in remission (PMR-C, n=5), and Healthy controls (HC, n=20) by RNAseq
analysis. (C) GO analysis demonstrated that inflammatory response (FDR 6.74x10⁻¹⁵,
58 significantly altered genes) and other 11 predominate pathways (PMR-A *vs.* HC).
(D) KEGG analysis showed cytokine-cytokine receptor interaction was the most

357 remarkable pathway (FDR 2.85×10^{-5} , 33 significantly altered genes) (PMR-A *vs.* HC).

358

359 FIG. 2 An abundant inflammatory genes which may activate JAK signaling.

360 (A) Volcano results demonstrated the many genes expression were significantly 361 increased, for example, TLR8, IL17RA, IL6R, CR1, TLR2, TLR4, CCR1, JAK2, IL1R1, IL1B, 362 S100A8, and S100A12 (PMR-A, n=11 vs. HC n=20). (B) They were all increased in 363 patients with PMR-A by Real-Time PCR analysis. Comparisons between two groups 364 were performed using the nonparametric Mann-Whitney test (*p<0.05, **p<0.01). 365 (C) Many genes were decreased in one representative patient with PMR. (D) She had 366 a significant decrease in PMR disease score, CRP, and ESR after the treatment with 367 tofacitinib.



